Cargando…
Safety and blood levels of daratumumab after switching from intravenous to subcutaneous administration in patients with multiple myeloma
The intravenous administration (IV) of daratumumab sometimes causes an infusion reaction and needs a long infusion time. Recently, a subcutaneous formulation (SC) of daratumumab, which has fewer infusion reactions and shorter administration time, was approved. However, because SC has a fixed dose, o...
| Autores principales: | , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer US
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10560139/ https://www.ncbi.nlm.nih.gov/pubmed/37721661 http://dx.doi.org/10.1007/s10637-023-01392-1 |